^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IDP-023

    i
    Other names: IDP-023, G-NK cell therapy, allogeneic FcεRIγ-deficient NK cells, G-NK cells
    Company:
    Indapta Therap
    Drug class:
    NK cell stimulant
    Related drugs:
    7ms
    IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov)
    P1, N=34, Suspended, Indapta Therapeutics, INC. | Initiation date: Jan 2025 --> Jun 2026 | Recruiting --> Suspended
    Trial initiation date • Trial suspension
    |
    cyclophosphamide • fludarabine IV • IDP-023 • Proleukin (aldesleukin) • Ocrevus (ocrelizumab)
    11ms
    IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov)
    P1, N=34, Recruiting, Indapta Therapeutics, INC. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • IDP-023 • Proleukin (aldesleukin) • Ocrevus (ocrelizumab)
    1year
    IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Indapta Therapeutics, INC.
    New P1 trial
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • IDP-023 • Proleukin (aldesleukin) • Ocrevus (ocrelizumab)
    2years
    IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers (clinicaltrials.gov)
    P1/2, N=128, Recruiting, Indapta Therapeutics, INC.
    New P1/2 trial • Combination therapy • Metastases
    |
    Rituxan (rituximab) • cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • IDP-023 • Proleukin (aldesleukin)
    over2years
    FcεRIγ-negative NK cells and association with improved outcomes in trastuzumab-treated patients. (ASCO 2023)
    G-NK cells are associated with improved OS and PFS in trastuzumab-treated patients from both clinical trials and real-world datasets, suggesting their presence may serve as a predictive marker for treatment efficacy. Adoptive transfer of g-NK cells is being explored to augment the efficacy of therapeutic monoclonal antibodies. >Datasets used in analyses: CALGB 40601 trial, C1-2 and C5; Finland Herceptin trial, C3-4 and C6-7; Molecular Taxonomy of Breast Cancer International Consortium, C8; Tempus Labs, RWD1-2.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Tempus xT Assay
    |
    Herceptin (trastuzumab) • IDP-023